Miranda Curtiss
Allergy & Immunology · Birmingham, ALNPI 1154688224
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by GSK at 42.1% of the total. Reporting peaked in 2023 at $270 and has fallen 82.4% since, to $48 in 2025. That places this record below the midpoint for allergy & immunology clinicians in AL, where the typical reported total is $8,006.
Across 13 payments — averaging $62.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$342
- AstraZeneca$301
- Sanofi$108
- Genentech, Inc.$43
- Insmed, Inc.$17
Across 8 payments — averaging $5615.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$45K
What the payments were for
- Food & beverage$79498%
- Education$172%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 5 | $342 |
| AstraZeneca | 5 | $301 |
| Sanofi | 1 | $108 |
| Genentech, Inc. | 1 | $43 |
| Insmed, Inc. | 1 | $17 |
How this compares
$811 in reported general payments places this provider in the 20th percentile of 30 allergy & immunology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 116 | $426,738 |
| NucalaMepolizumab | 40 | $330,138 |
| Dupixent SyringeDupilumab | 33 | $119,952 |
| TezspireTezepelumab-Ekko | 27 | $110,872 |
| XolairOmalizumab | 30 | $92,862 |
| Fasenra PenBenralizumab | 16 | $86,205 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $38,051 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $10,664 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $8,812 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $4,783 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $3,050 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 92 | $2,823 |
| Wixela InhubFluticasone Propion/Salmeterol | 16 | $1,887 |
| Montelukast Sodium | 73 | $1,059 |
| Azelastine Hcl | 20 | $869 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta | $342 | $378,854110 claims |
| AstraZenecaTezspire, Breztri Aerosphere | $301 | $119,68441 claims |
| Genentech, Inc.Xolair | $43 | $92,86230 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 30 allergy & immunology providers in Alabama.
Other allergy & immunology in Birmingham
- Thomas AtkinsonBirmingham$53K
- Njeri MainaBirmingham$44K
- Michael PolcariBirmingham$39K
- Carol SmithBirmingham$11K
- Tracy HwangpoBirmingham$5K
- Amy CajacobBirmingham$4K
- William MasseyBirmingham$3K
- Elizabeth GeorgeBirmingham$3K
- Kathleen GrisantiBirmingham$1K
- John AndersonHomewood$789K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.